We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIndivior PLC

Indivior PLC

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2025-08-22T16:00:08.000588Z
Market Cap
1604.53M

Momentum Score

…

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1125.00
Low
2020.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1238.00
Dividend Yield
-
Revenue TTM
1042.00M
Revenue Per Share
7.61
Gross Profit TTM
742.00M
Debt / Equity
5.43
ROE
-231.53%
Net Debt
-497.00M
ROCE
-12.13%
Diluted EPS TTM
-1.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -95.00M 190.00M -173.00M 180.00M 278.00M
Net income -53.00M 205.00M -148.00M 134.00M 275.00M
Selling general administrative 545.00M 226.00M 447.00M 196.00M 271.00M
Selling and marketing expenses 218.00M 192.00M 202.00M 199.00M 205.00M
Gross profit 742.00M 664.00M 550.00M 645.00M 877.00M
Reconciled depreciation 21.00M 22.00M 26.00M 28.00M 40.00M
Ebit -91.00M 213.00M -156.00M 178.00M 306.00M
Ebitda -51.00M 207.00M -121.00M 230.00M 346.00M
Depreciation and amortization 40.00M -6.00M 35.00M 52.00M 40.00M
Operating income -91.00M 213.00M -156.00M 178.00M 316.00M
Other operating expenses 992.00M 610.00M 803.00M 607.00M 689.00M
Interest expense 29.00M 27.00M 26.00M 22.00M 28.00M
Tax provision -42.00M -15.00M -25.00M 46.00M 3.00M
Interest income 19.00M 4.00M 9.00M 24.00M 17.00M
Net interest income -10.00M -23.00M -17.00M 2.00M -14.00M
Extraordinary items - - - - 2.00M
Income tax expense -42.00M -15.00M -25.00M 46.00M 3.00M
Total revenue 901.00M 791.00M 647.00M 785.00M 1005.00M
Total operating expenses 833.00M 483.00M 706.00M 467.00M 561.00M
Cost of revenue 159.00M 127.00M 97.00M 140.00M 128.00M
Total other income expense net -4.00M -23.00M -17.00M 2.00M -38.00M
Net income from continuing ops -53.00M 205.00M -148.00M 134.00M 275.00M
Net income applicable to common shares -53.00M 205.00M -148.00M 134.00M 275.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1769.00M 1832.00M 1531.00M 1652.00M 1547.00M
Intangible assets 70.00M 82.00M 62.00M 72.00M 84.00M
Other current assets 13.00M 14.00M 33.00M 227.00M 327.00M
Total liab 1718.00M 1629.00M 1449.00M 1443.00M 1481.00M
Total stockholder equity 51.00M 203.00M 82.00M 209.00M 66.00M
Other current liab 972.00M 61.00M 48.00M 71.00M 218.00M
Common stock 68.00M 70.00M 73.00M 73.00M 73.00M
Capital stock 68.00M 70.00M 73.00M 73.00M 73.00M
Retained earnings 1303.00M 1438.00M 1311.00M 1449.00M 1315.00M
Other liab 433.00M 550.00M 577.00M 417.00M 426.00M
Other assets 257.00M 211.00M 179.00M 113.00M 77.00M
Cash 774.00M 1102.00M 858.00M 1060.00M 924.00M
Total current liabilities 1019.00M 804.00M 599.00M 742.00M 818.00M
Current deferred revenue - 595.00M 519.00M 623.00M -
Net debt -497.00M -816.00M -573.00M -767.00M -683.00M
Short term debt 11.00M 11.00M 12.00M 9.00M 4.00M
Short long term debt 3.00M 3.00M 4.00M 4.00M 4.00M
Short long term debt total 277.00M 286.00M 285.00M 293.00M 241.00M
Other stockholder equity -1320.00M -1305.00M -1302.00M -1313.00M -1270.00M
Property plant equipment 85.00M 95.00M 103.00M 107.00M 57.00M
Total current assets 1259.00M 1444.00M 1187.00M 1360.00M 1329.00M
Net tangible assets -19.00M 121.00M 20.00M 137.00M -18.00M
Short term investments 119.00M - - - -
Net receivables 239.00M 233.00M 203.00M 192.00M 318.00M
Long term debt 237.00M 239.00M 230.00M 233.00M 237.00M
Inventory 114.00M 95.00M 93.00M 73.00M 78.00M
Accounts payable 36.00M 137.00M 20.00M 39.00M 557.00M
Accumulated other comprehensive income - - - -60.00M -52.00M
Common stock total equity - - 73.00M 73.00M 73.00M
Non currrent assets other 157.00M 84.00M 82.00M 50.00M 33.00M
Non current assets total 510.00M 388.00M 344.00M 292.00M 218.00M
Capital lease obligations 37.00M 44.00M 51.00M 56.00M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -223.00M -14.00M -4.00M -2.00M -4.00M
Change to liabilities -98.00M 201.00M -103.00M -101.00M 58.00M
Total cashflows from investing activities -223.00M -14.00M -4.00M -2.00M -4.00M
Net borrowings -12.00M 6.00M -11.00M -13.00M -240.00M
Total cash from financing activities -100.00M -94.00M -10.00M -13.00M -237.00M
Change to operating activities 269.00M 269.00M 85.00M -64.00M 35.00M
Net income -85.00M 213.00M -156.00M 178.00M 275.00M
Change in cash -328.00M 244.00M -202.00M 136.00M 61.00M
Begin period cash flow 1102.00M 858.00M 1060.00M 924.00M 863.00M
End period cash flow 774.00M 1102.00M 858.00M 1060.00M 924.00M
Total cash from operating activities -4.00M 353.00M -193.00M 151.00M 303.00M
Issuance of capital stock 2.00M 1.00M 1.00M 0.00M 3.00M
Depreciation 21.00M 22.00M 26.00M 28.00M 40.00M
Other cashflows from investing activities - - - 1.00M 1.00M
Change to inventory -25.00M -3.00M -16.00M 7.00M -31.00M
Change to account receivables -21.00M -25.00M 15.00M 79.00M -33.00M
Sale purchase of stock -90.00M -101.00M 1.00M - 3.00M
Other cashflows from financing activities -9.00M 242.00M -7.00M -9.00M -4.00M
Change to netincome -97.00M -47.00M -52.00M 68.00M -41.00M
Capital expenditures 6.00M 34.00M 4.00M 7.00M 41.00M
Change in working capital 125.00M 173.00M -19.00M -79.00M 29.00M
Stock based compensation 16.00M 11.00M 8.00M 3.00M 15.00M
Other non cash items -81.00M -66.00M -52.00M 21.00M -56.00M
Free cash flow -10.00M 319.00M -197.00M 144.00M 262.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLN
Haleon PLC		 -4.20
1.10%		 376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 4.00
0.24%		 1704.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 -2.00
0.95%		 208.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 -
-%		 4.25 - 106.38 11.72 159.47 12.12 -4.15

Profile*

Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235

804 379 1090

https://www.indivior.com

1000

Name Title Year Born
Mr. Mark Crossley CEO & Exec. Director NA
Mr. Ryan Preblick CFO & Exec. Director NA
Dr. Christian Heidbreder Chief Scientific Officer NA
Mr. Jason Thompson VP of Investor Relations NA
Ms. Cynthia Cetani Chief Integrity & Compliance Officer NA
Mr. Jeffrey W. Burris Chief Legal Officer 1972
Mr. Jon Fogle Chief HR Officer NA
Mr. Richard Simkin Chief Commercial & Strategy Officer NA
Mr. Hillel West Chief Manufacturing & Supply Officer NA
Ms. Nina DeLorenzo Chief Global Impact Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…